Showing 1 - 7 results of 7 for search 'Kerstin Schaefer', query time: 0.04s Refine Results
  1. 1
    An In Vitro Model to Investigate the Potential of Solid Dispersions to Form Pharmacobezoars

    An In Vitro Model to Investigate the Potential of Solid Dispersions to Form Pharmacobezoars by Hannes Gierke, Kerstin Schaefer, Lukas Gerlich, Ann-Cathrin Willmann, Verena Bialetzki, Georg Boeck, Teresa Pfrommer, Thomas Nolte, Werner Weitschies

    Published 2022-11-01
    Get full text
    Article
  2. 2
    Evaluation of Pharmacobezoar Formation from Suspensions of Spray-Dried Amorphous Solid Dispersions: An MRI Study in Rats

    Evaluation of Pharmacobezoar Formation from Suspensions of Spray-Dried Amorphous Solid Dispersions: An MRI Study in Rats by Hannes Gierke, Susan Mouchantat, Sabine Berg, Michael Grimm, Stefan Hadlich, Marie-Luise Kromrey, Thomas Nolte, Teresa Pfrommer, Vincent Rönnpagel, Adrian Rump, Kerstin Schaefer, Ann-Cathrin Willmann, Werner Weitschies

    Published 2023-03-01
    Get full text
    Article
  3. 3
    P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13

    P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM T... by Heike Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino Lars Teichmann, Hendrik Poeck, Jörg Westermann, Kerstin Schaefer-Eckart, Thomas Heinicke, Hubert Serve, Monika Brüggemann, Stefan Schwartz, Thomas Burmeister, Nicola Gökbuget

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

    Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD by Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, Johannes Krisam, Martin Görner, Mathias Hänel, Christoph Röllig, Maxi Wass, Sebastian Scholl, Mark Ringhoffer, Alexander Reichart, Björn Steffen, Sabine Kayser, Jan-Henrik Mikesch, Kerstin Schaefer-Eckart, Jörg Schubert, Thomas Geer, Sonja Martin, Meinhard Kieser, Tim Sauer, Katharina Kriegsmann, Michael Hundemer, Hubert Serve, Martin Bornhäuser, Carsten Müller-Tidow, Richard F. Schlenk

    Published 2023-09-01
    Get full text
    Article
  5. 5
    The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis

    The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis by Daphne Mytilineos, Daphne Mytilineos, Daphne Mytilineos, Chrysanthi Tsamadou, Chrysanthi Tsamadou, Christine Neuchel, Christine Neuchel, Uwe Platzbecker, Donald Bunjes, Natalie Schub, Eva Wagner-Drouet, Gerald Wulf, Nicolaus Kröger, Niels Murawski, Hermann Einsele, Kerstin Schaefer-Eckart, Sebastian Freitag, Jochen Casper, Martin Kaufmann, Mareike Dürholt, Bernd Hertenstein, Stefan Klein, Mark Ringhoffer, Carlheinz R. Mueller, Carlheinz R. Mueller, Sandra Frank, Hubert Schrezenmeier, Hubert Schrezenmeier, Daniel Fuerst, Daniel Fuerst, Joannis Mytilineos, Joannis Mytilineos, Joannis Mytilineos

    Published 2021-01-01
    Get full text
    Article
  6. 6
    Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

    Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction ther... by Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, Martina Crysandt, Andreas Rank, Dirk Behringer, Lino Teichmann, Martin Görner, Ralf-Ulrich Trappe, Christoph Röllig, Stefan Krause, Maher Hanoun, Olaf Hopfer, Gerhard Held, Sebastian Buske, Lars Fransecky, Sabine Kayser, Christoph Schliemann, Kerstin Schaefer-Eckart, Yousef Al-Fareh, Jörg Schubert, Thomas Geer, Martin Kaufmann, Arne Brecht, Dirk Niemann, Meinhard Kieser, Martin Bornhäuser, Uwe Platzbecker, Hubert Serve, Claudia D. Baldus, Carsten Müller-Tidow, Richard F. Schlenk

    Published 2021-11-01
    Get full text
    Article
  7. 7
    P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)

    P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA) by Katja Sockel, Anke Mütherig, Martina Crysandt, Mathias Hänel, Richard Noppeney, Kerstin Schaefer-Eckart, Martin Kaufmann, Christoph Röllig, Johannes Schetelig, Sven Zukunft, Frank Fiebig, Aristoteles Giagounidis, Sebastian Scholl, Andreas Lück, Kathrin Rieger, Katharina Götze, Thomas Geer, Philipp Kiewe, Carsten Müller-Tidow, Hubert Serve, Claudia Baldus, Ulrich Kaiser, Stefan Mahlmann, Burkhard Schmidt, Stefani Parmentier, Thomas Illmer, Ruth Seggewiß-Bernhardt, Alexander Kiani, Hartmut Linde, Heinz Dürk, Michael Kramer, Desiree Kunadt, Katharina Schmidt-Brücken, Jana Hase, Susann Helas, Jan Moritz Middeke, Malte von Bonin, Uta Oelschlaegel, Gerhard Ehninger, Christian Thiede, Martin Bornhauser, Uwe Platzbecker

    Published 2023-08-01
    Get full text
    Article

Search Tools: